Chronic inflammatory demyelinating polyneuropathy (cidp)
Drug research and approvals for chronic inflammatory demyelinating polyneuropathy (cidp): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 36 studies of chronic inflammatory demyelinating polyneuropathy (cidp) are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, and FDA has 5 approved and 5 open orphan designations naming it.
- Recruiting worldwide: 36
- Trials authorized in Canada: 21
- FDA orphan approvals: 5
- EU medicines: 0
Recruiting Now
Newest start dates first, of 36 recruiting on ClinicalTrials.gov ↗- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic…NCT06752356 · Phase 3 · Kedrion S.p.A. · starts Nov 1, 2026
- Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating PolyneuropathyNCT07882797 · Not reported · Heinrich-Heine University, Duesseldorf · starts Oct 23, 2026
- Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentNCT07304154 · Phase 1 · Kite, A Gilead Company · starts Apr 10, 2026
- A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic…NCT07540221 · Phase 3 · Grifols Therapeutics LLC · starts Apr 2, 2026
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory…NCT07526493 · Phase 1 · Tongji Hospital · starts Apr 1, 2026
- Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesNCT07273903 · Not reported · Heinrich-Heine University, Duesseldorf · starts Jan 15, 2026
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune DiseasesNCT07337785 · Early Phase 1 · Tongji Hospital · starts Dec 12, 2025
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPNCT07091630 · Phase 3 · argenx · starts Sep 16, 2025
- Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT07154524 · Not reported · University of Ulm · starts Aug 27, 2025
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPNCT06920004 · Phase 3 · argenx · starts Aug 22, 2025
Trials Authorized in Canada
The 10 newest of 21; search them all in Canada trials| May 29, 2026 | A phase 3, randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety of inebilizumab in participants with chronic…UPLIZNA (INEBILIZUMAB) | Amgen | Pending |
| Oct 28, 2025 | A phase 3, randomized, double-blinded, placebo-controlled study evaluating the efficacy and safety of empasiprubart iv in adults with chronic inflammatory…EMPASIPRUBART (ARGX-117) | argenx US, Inc. | Pending |
| Aug 8, 2025 | Phase 3, randomized, double-blinded, double-dummy study evaluating the efficacy and safety of intravenous empasiprubart versus intravenous immunoglobulin in…EMPASIPRUBART (ARGX-117) / OCTAGAM | argenx US, Inc. | Ongoing |
| May 8, 2025 | A phase 2, open-label study to evaluate the safety, tolerability, and efficacy of intravenous nvg-2089 in participants with chronic inflammatory demyelinating…NVG-2089 | NUVIG THERAPEUTICS, INC. | Closed |
| Mar 7, 2025 | A phase 2, open-label, proof-of-concept study to investigate the efficacy, safety and tolerability of tak-411 in adult subjects with chronic inflammatory…TAK-411 | Takeda Pharmaceuticals USA | Ongoing |
| Feb 14, 2025 | Long-term extension study to evaluate the safety and efficacy of riliprubart (sar445088) in participants with chronic inflammatory demyelinating polyneuropathy…RILIPRUBART (SAR445088) | SANOFI-AVENTIS CANADA INC | Pending |
| Jun 13, 2024 | A phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (ivig) in participants with chronic…RILIPRUBART (SAR445088) | SANOFI-AVENTIS CANADA INC | Ongoing |
| Apr 26, 2024 | A phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory…RILIPRUBART (SAR445088) | SANOFI-AVENTIS CANADA INC | Ongoing |
| Jun 9, 2023 | A phase 2b, multi-center, randomized, quadruple-blind, placebo-controlled study of batoclimab treatment in adult participants with active chronic inflammatory…BATOCLIMAB (IMVT-1401) | IMMUNOVANT SCIENCES GMBH | Closed |
| Mar 3, 2022 | Phase 2/3, multistage, multicenter, randomized, double-blind, placebocontrolled parallel group withdrawal study to evaluate the efficacy and safety of…NIPOCALIMAB (M281) | Johnson & Johnson | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Apr 10, 2025 | Vyvgart Hytrulotreatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | argenx BV | Approved |
| Jun 21, 2024 | Vyvgart Hytrulotreatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | argenx BV | Approved |
| Jan 12, 2024 | HyQviatreatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability… | Takeda Development Center Americas, Inc. | Approved |
| Mar 15, 2018 | HizentraIndicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to… | CSL Behring | Approved |
| Sep 12, 2008 | Gamunex-CTreatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for… | Grifols Therapeutics, Inc. | Approved |
| Mar 20, 2024 | prednisoneTreatment of Chronic Inflammatory Demyelinating Polyneuropathy | Sarcomed AB | Designated |
| Oct 14, 2021 | nipocalimabTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adult patients | Janssen Research & Development, LLC | Designated |
| Jul 21, 2021 | Anti-C1s Humanized IgG4 Monoclonal AntibodyTreatment of chronic inflammatory demyelinating polyneuropathy | Sanofi Genzyme | Designated |
| Feb 14, 2018 | recombinant humanized IgG4 monoclonal antibody against…Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP) | GeNeuro S.A. | Designated |
| Jul 14, 2015 | recombinant multimerized human IgG1 FcTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP). | Gliknik Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA